TABLE 3.

Characteristics of patients who had probable or proven invasive fungal infections while receiving posaconazole prophylaxis^a

Patient	Age >65 yr	Sex	Underlying diagnosis	HSCT	Posaconazole formulation	EORTC classification	Probable criteria	Site of infection	Identified fungal organism	No. of days after start of prophylaxis	Posaconazole level (μg/ml)
1	Yes	F	APL	No	Suspension	Probable	Host factor, neutropenia; clinical criteria, tracheobronchial plaques on bronchoscopy; mycological criteria, Aspergillus fumigatus from bronchoalveolar lavage fluid	Lung/trachea	Aspergillus fumigatus	15	NC
2	No	F	CML	No	Suspension	Probable	Host factor, neutropenia; clinical criteria, CT of the chest with multiple pulmonary nodules and focal peribronchial consolidation; mycological criteria, positive galactomannan	Lung	Positive galactomannan only	18	0.28
3	Yes	M	AML	No	Suspension	Proven		Skin	Fusarium proliferatum	17	1.82
4	Yes	M	AML	No	Tablet	Probable	Host factor, neutropenia; clinical criteria, CT with numerous bilateral small consolidative nodules; mycological criteria, positive galactomannan	Lung	Positive galactomannan only	25	1.80
5	Yes	M	AML	No	Tablet	Proven		Lung	Positive cryptococcal antigen only	13	NC
6	No	M	GVHD	Allogeneic (2004)	Suspension	Proven		Blood	Candida glabrata	12	1.07
7	No	M	AML	No	Tablet	Proven		Sinuses	Mucor sp.	66	0.90
8	Yes	M	AML	Allogeneic (2013)	Tablet	Proven		Sinuses	Zygomyces sp.	13	NC
9	No	M	AML	No	Suspension	Proven		Lung	Aspergillus niger	5	NC
10	No	M	AML	No	Suspension	Probable	Host factor, neutropenia; clinical criteria, multifocal bilateral inflammatory nodularity and consolidation compatible with multifocal pneumonia; mycological criteria, positive galactomannan	Lung	Positive galactomannan only	7	NC
11	No	F	Allogeneic HSCT	Allogeneic (2012)	Suspension	Proven		Lung	Aspergillus sp.	44	2.09
12	No	M	GVHD	Allogeneic (2014)	Tablet	Proven		Blood	Candida glabrata	78	1.20
13	No	M	AML	Allogeneic (2012)	Tablet	Proven		Sinuses	No culture growth	39	NC
14	Yes	M	AML	No	Tablet	Proven		Blood	Candida tropicalis	13	1.60

^aData are for 14 patients. F, female; M, male; HSCT, hematopoietic stem cell transplantation; EORTC, European Organization for Research and Treatment of Cancer; CT, computed tomography; APL, acute promyelocytic leukemia; CML, chronic myeloid leukemia; AML, acute myeloid leukemia; GVHD, graft-versus-host disease; NC, not collected.